Ignite Creation Date:
2025-12-25 @ 1:23 AM
Ignite Modification Date:
2026-02-24 @ 1:44 AM
Study NCT ID:
NCT02280993
Status:
UNKNOWN
Last Update Posted:
2018-03-13
First Post:
2014-08-19
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Phase I/II Feasibility Study Combining Brentuximab Vedotin With Second Line Salvage Chemotherapy (DHAP) in Hodgkin Lymphoma Patients
Sponsor:
Marjolein Spiering
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2014-05
Start Date Type:
ACTUAL
Primary Completion Date:
2018-11
Primary Completion Date Type:
ESTIMATED
Completion Date:
2020-05
Completion Date Type:
ESTIMATED
First Submit Date:
2014-08-19
First Submit QC Date:
None
Study First Post Date:
2014-11-03
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2018-03-12
Last Update Post Date:
2018-03-13
Last Update Post Date Type:
ACTUAL